Guillain-Barre Syndrome study: Tanruprubart
Official title An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
ClinicalTrials.gov ID: NCT07020819
What this study is testing
What is Tanruprubart?
an investigational IV infusion being studied as a potential treatment for Guillain-Barre Syndrome
Also referred to as ANX005.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing how well a new drug works. It also checks how safe the drug is for patients.
- Who it's for
- You may be able to join if you have Guillain-Barré Syndrome.
- What's involved
- You would get the drug tanruprubart. The team will check how your body handles it.
- Time commitment
- The source text does not say how long the study lasts.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 8 to 85
You may be able to join if
- Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.
- Onset of GBS-related weakness ≤10 days before start of infusion on Day 1
- GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1. Key
You likely can't join if
- Previous or planned treatment with either plasma exchange or IV immunoglobulin within 90 days of Day 1.
- Diagnosis of any form of GBS that does not involve weakness of the extremities. Other protocol-defined criteria may apply.
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Carlsbad, California, United States
- Loma Linda, California, United States
- Orange, California, United States
- Palo Alto, California, United States
- Aurora, Colorado, United States
- Washington D.C., District of Columbia, United States
- Jacksonville, Florida, United States
- Kansas City, Kansas, United States
- Shreveport, Louisiana, United States
- Worcester, Massachusetts, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Rochester, Minnesota, United States
- Lebanon, New Hampshire, United States
- Albany, New York, United States
- Durham, North Carolina, United States
- Cleveland, Ohio, United States
- Philadelphia, Pennsylvania, United States
+ 9 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 8 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Scottsdale, Arizona, United States; Carlsbad, California, United States; Loma Linda, California, United States; Orange, California, United States; Palo Alto, California, United States and 23 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.